$5.88 Billion is the total value of Avoro Capital Advisors LLC's 41 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 15.8% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
HZNP | Buy | HORIZON THERAPEUTICS PLC | $1,001,629,000 | +1.6% | 9,295,000 | +3.3% | 17.05% | +10.1% |
MRTX | Buy | MIRATI THERAPEUTICS INC | $744,452,000 | -15.8% | 5,075,000 | +1.5% | 12.67% | -8.8% |
UTHR | Buy | UNITED THERAPEUTICS CORP | $655,803,000 | +18.4% | 3,035,000 | +1.2% | 11.16% | +28.3% |
APLS | Buy | APELLIS PHARMACEUTICALS INC | $404,507,000 | +145.5% | 8,555,555 | +71.1% | 6.88% | +165.9% |
ARGX | Buy | ARGENX SEsponsored adr | $337,933,000 | +18.2% | 965,000 | +2.0% | 5.75% | +28.1% |
SRPT | Buy | SAREPTA THERAPEUTICS INC | $281,406,000 | +21.7% | 3,125,000 | +25.0% | 4.79% | +31.9% |
ASND | Buy | ASCENDIS PHARMAsponsored adr | $269,060,000 | -14.7% | 2,000,000 | +1.0% | 4.58% | -7.6% |
BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $247,380,000 | +70.7% | 2,800,000 | +49.3% | 4.21% | +85.0% |
FOLD | Buy | AMICUS THERAPEUTICS INC | $213,675,000 | +26.6% | 18,500,000 | +4.6% | 3.64% | +37.1% |
ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $182,299,000 | +13.6% | 1,075,000 | +26.5% | 3.10% | +23.1% |
IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $165,606,000 | -21.0% | 8,675,000 | +2.1% | 2.82% | -14.4% |
XENE | Buy | XENON PHARMACEUTICALS INC | $155,731,000 | +179.2% | 4,985,000 | +36.6% | 2.65% | +202.5% |
ISEE | Buy | IVERIC BIO INC | $121,220,000 | +5.1% | 7,250,000 | +2.1% | 2.06% | +13.9% |
XBI | New | SPDR SERIES TRUST - S&P BIOTECHetf | $117,558,000 | – | 1,050,000 | +100.0% | 2.00% | – |
SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $47,611,000 | +61.3% | 2,175,000 | +40.8% | 0.81% | +74.6% |
PRAX | Buy | PRAXIS PRECISION MEDICINES INC | $35,066,000 | +18.5% | 1,780,000 | +11.2% | 0.60% | +28.4% |
DSGN | Buy | DESIGN THERAPEUTICS INC | $35,029,000 | +62.4% | 1,636,100 | +11.4% | 0.60% | +75.8% |
KYMR | Buy | KYMERA THERAPEUTICS INC | $34,920,000 | +30.4% | 550,000 | +20.7% | 0.59% | +41.1% |
KRYS | New | KRYSTAL BIOTECH INC | $33,226,000 | – | 475,000 | +100.0% | 0.56% | – |
RNA | Buy | AVIDITY BIOSCIENCES INC | $29,237,000 | +3.2% | 1,230,000 | +7.0% | 0.50% | +11.9% |
New | IO BIOTECH INC | $10,243,000 | – | 2,055,883 | +100.0% | 0.17% | – | |
SRPT | Buy | SAREPTA THERAPEUTICS INCcall | $2,910,000 | +32.6% | 300,000 | +50.0% | 0.05% | +47.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
ARGENX SE | 26 | Q3 2023 | 9.5% |
IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G/A | 2024-04-23 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.